Regulus Therapeutics Inc. (NASDAQ:RGLS) announced updates to its pre-clinical and clinical development programs. “We are squarely focused on taking the steps necessary to advance our pipeline and continue building shareholder value. To that end, we recognize that we must be disciplined in our investment choices and focus our resources and capital on our most promising discovery and development programs, including the application of important development, regulatory and commercial considerations,” said Jay Hagan, President and Chief Executive Officer of Regulus. “MicroRNA therapeutics have the potential to become an important new class of drugs with broad therapeutic application. Regulus’ focus will be in diseases with significant unmet medical need in organs to which we have been able to preferentially deliver oligonucleotide therapeutics effectively, such as the liver and kidney.”
On Monday Regulus Therapeutics Inc. (NASDAQ:RGLS) share price closed at $1.17. Company return on equity (ROE) is -126.00%. Regulus Therapeutics Inc. (NASDAQ:RGLS) is -80.26% away from its 52 week high and its 52 week range is $0.94 – $5.95.
SITO Mobile, Ltd. (NASDAQ:SITO) announced that the independent inspector of elections, which was appointed by the Company in connection with the previously-announced consent solicitation by Stephen D. Baksa, Thomas M. Candelaria and other participants, has certified written consents representing more than 57% of the Company’s outstanding shares to remove five of the six members of the Company’s Board of Directors, elect five new directors to the Company’s Board of Directors and amend and restate the Company’s Bylaws. Accordingly, effective immediately, Betsy Bernard, Richard O’Connell, Jonathan E. Sandelman, Lowell W. Robinson and Joseph Beatty have been removed from the Company’s Board.
SITO Mobile, Ltd. (NASDAQ:SITO) traded 247385 shares and its share price fell -5.95% to close at $3.48. Company has 1.00% insider ownership. SITO Mobile, Ltd. (NASDAQ:SITO) quarterly performance is 56.76% while its year to date (YTD) performance is -5.69%.
On Monday shares of Eaton Corporation plc (NYSE:ETN) ended up at $75.77. This year Company’s Earnings per Share (EPS) growth is -0.60% and next year’s EPS growth is 10.39%. Beta of Eaton Corporation plc (NYSE:ETN) is 1.34 while company weekly performance is -1.30%.
GlaxoSmithKline plc (NYSE:GSK) fell -0.32% to close at $43.37 on 12 June. Its return on assets (ROA) is 2.90% while return on investment (ROI) is 8.60%. GlaxoSmithKline plc (NYSE:GSK) price to sales (P/S) ratio is 2.82.